Elan Pharmaceuticals, Inc. is a wholly-owned subsidiary of Elan Corporation, plc (NYSE: ELAN). Elan is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges.
Helix BioPharma Corp. is a Canada-based biopharmaceutical company developing products for the treatment of cancer and prevention of cancer. Its revenue consists of product revenue, including the distribution in Canada of Klean-Prep and Orthovisc, and royalty payments from Helsinn-Birex relating to its license of the Company’s Klean-Prep technology. The Company is principally focusing its resources on pursuing the clinical development of two emerging drug products with distinct anti-cancer applications: L-DOS47 and Topical Interferon Alpha-2b. L-DOS47 is the first drug product candidate to emerge from the Company’s DOS47 development program, and is under development for the treatment of lung adenocarcinoma, the most common form of lung cancer. Topical Interferon Alpha-2b is under development for two human papilloma virus (HPV)-induced indications: low-grade squamous intraepithelial cervical lesions (LSIL) and ano-genital warts (AGW). (Source: ARS)
BioXell SpA is an Italy-based biopharmaceutical company. The Company focuses on the research, development and commercialization of therapies for various medical needs. It is active in a range of therapeutic areas, such as urology (benign prostatic hyperplasia, overactive bladder and male infertility), inflammation (sepsis, inflammatory bowel disease, post-surgical adhesions), pain and other therapeutic areas (secondary hyperparathyroidism and osteoporosis). BioXell S.p.A’s products, which are in the preclinical and development phases, include Elocalcitol and BXL746, a Vitamin D3 analogues for the treatment of urological disorders; MNAC13 applied for treatment of chronic pain, and TREM-1, for the treatment of sepsis. The Company has one wholly owned subsidiary, BioXell Inc that develops the Vitamin D3 platform.
Dimethaid Research Inc. is a fully integrated pharmaceutical company headquartered in Canada with subsidiaries in Europe, Asia and the Caribbean. The company is focused on the commercialization of therapeutics designed to produce minimal side effects. Dimethaid is engaged in all stages of pharmaceutical development, from R&D, through clinical and regulatory filing, to full-scale manufacturing and marketing. Dimethaid Research Inc. trades on the Toronto Stock Exchange under the symbol DMX.
Ardana is an emerging pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, in order to address the areas of considerable unmet needs in this $25 billion-plus market. Since Ardana's foundation in July 2000 we have pursued a four-part strategy to create value from the business by: Maintaining a broad and balanced portfolio to manage risk, focusing on the therapeutic area of human reproductive health; Actively pursuing an in-licensing and acquisition programme for products and technologies to maintain a robust pipeline, including near-term commercial products and potential high value development candidates; Retaining value in our portfolio by building a sales and marketing capability in leading European markets, through both our own infrastructure and partnerships; and Maintaining a lean organisation by selective outsourcing in order to achieve flexibility. Ardana operates a fully integrated pharmaceutical business model from research right through to sales and marketing. Its experienced management team operates a virtual model in the areas of research, development (both pre clinical and clinical), manufacturing, regulatory and logistics using validated out-sourced suppliers to complete the work programmes designed internally. Ardana has its own salesforce in the UK and marketing partners in Europe. Currently Ardana's key customers are endocrinologists and urologists and, as the portfolio expands, the customer profile will include other reproductive health specialists such as obstetricians and gynaecologists.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory